>i am currently invested in mrk, and looking to add alot more over the next few months. i feel mrk longterm, combined with its pipeline seems like very good buy here.<
MRK has a better pipeline than most investors think, IMO. A few additional comments:
1. Unlike several Big Pharma, MRK is not pulling back from the large, primary-care indications. Any successes MRK achieves in this area ought therefore to be magnified by the relative lack of competition.
2. For reasons that are not entirely clear, the Zetia/Vytorin franchise has not suffered outside the US. Further, the Zetia + Lipitor combination pill due in 2011 could be a substantial product.
3. One of the few areas Peter Kim declined to discuss on the webcast was MRK’s program in AD. Why? I would hazard a guess that MRK does not want to tip off WYE, ELN, and LLY about what it knows.
4. If the GlycoFi technology works as advertised, MRK’s biologics program—note that I do not call it an FoB program—could be a major contributor to revenue in five or six years.
Market Data 
Markets 
AI
